These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8832618)

  • 1. Further evidence of favorable effects of gemfibrozil on the lipid profile in renal allograft recipients.
    Ok E; Kursat S; Alev M; Tobu M; Tokat Y; Akcicek F; Hoscoskun C; Basci A
    Nephron; 1996; 73(3):491-2. PubMed ID: 8832618
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of diet and gemfibrozil on posttransplant hyperlipidemia in renal transplant recipients.
    Sapan M; Ozben B; Yakupoglu G; Suleymanlar G; Ozben T
    J Investig Med; 2009 Feb; 57(2):456-9. PubMed ID: 19174703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of gemfibrozil on lipid and hemostatic factors in CAPD patients.
    Lee MS; Kim SM; Kim SB; Lee SK; Park JS; Yang WS
    Perit Dial Int; 1999; 19(3):280-3. PubMed ID: 10433170
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease.
    Samuelsson O; Attman PO; Knight-Gibson C; Kron B; Larsson R; Mulec H; Weiss L; Alaupovic P
    Nephron; 1997; 75(3):286-94. PubMed ID: 9069450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Gemfibrozil in the elderly. Effects on lipid metabolism].
    Brosche T; Kipfmüller G
    Fortschr Med; 1996 May; 114(13):157-60. PubMed ID: 8964557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Helsinki Heart Study].
    Sekiya M; Ishibashi S
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():404-9. PubMed ID: 11347103
    [No Abstract]   [Full Text] [Related]  

  • 7. [The effects of Xuezhikang on serum lipid profile, thromboxane A2 and prostacyclin in patients with hyperlipidemia].
    Jian J; Hao X; Deng C; Zhou H; Lin J
    Zhonghua Nei Ke Za Zhi; 1999 Aug; 38(8):517-9. PubMed ID: 11798687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fibrate-induced changes in the serum lipid contents of individual C16 and C18 fatty acids in patients with hyperlipidemia].
    Titov VN; Arapbaeva AA; Kukharchuk VV; Balakina MV; Tishinin MA; Ameliushkina VA
    Klin Lab Diagn; 2006 Apr; (4):3-8. PubMed ID: 16756155
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study.
    Jen SL; Chen JW; Lee WL; Wang SP
    Zhonghua Yi Xue Za Zhi (Taipei); 1997 Apr; 59(4):217-24. PubMed ID: 9216117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of effect of gemfibrozil on cyclosporine blood concentrations in kidney-transplanted patients.
    Pisanti N; Stanziale P; Imperatore P; D'Alessandro R; De Marino V; Capone D; De Marino V
    Am J Nephrol; 1998; 18(3):199-203. PubMed ID: 9627035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased prevalence of atherosclerotic wall changes in patients with hyperlipidaemia after renal transplantation.
    Jogestrand T; Fehrman-Ekholm I; Angelin B; Berglund L; Gäbel H
    J Intern Med; 1996 Feb; 239(2):177-80. PubMed ID: 8568487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-lowering therapy and long-term survival in heart transplantation.
    Stapleton DD; Mehra MR; Dumas D; Smart FW; Milani RV; Lavie CJ; Ventura HO
    Am J Cardiol; 1997 Sep; 80(6):802-5. PubMed ID: 9315598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia.
    Hussain M; Shad MN; Akhtar L
    J Pak Med Assoc; 2017 Dec; 67(12):1884-1888. PubMed ID: 29256535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decrease in high density lipoprotein cholesterol (HDL-C) levels following gemfibrozil therapy.
    Lacko AG; Kudchodkar BJ; Loney WW; Clearfield MB; Weis S
    Clin Chem Lab Med; 1998 Jun; 36(6):389-92. PubMed ID: 9711427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperlipidemia after renal transplantation: treatment with gemfibrozil.
    Chan TM; Cheng IK; Tam SC
    Nephron; 1994; 67(3):317-21. PubMed ID: 7936022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities.
    Henry K; Melroe H; Huebesch J; Hermundson J; Simpson J
    Lancet; 1998 Sep; 352(9133):1031-2. PubMed ID: 9759748
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of fenofibrate and gemfibrozil on plasma homocysteine.
    Bostom AG
    Lancet; 2001 Nov; 358(9295):1811-2. PubMed ID: 11734262
    [No Abstract]   [Full Text] [Related]  

  • 18. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis.
    Basaranoglu M; Acbay O; Sonsuz A
    J Hepatol; 1999 Aug; 31(2):384. PubMed ID: 10453959
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of fenofibrate and gemfibrozil on plasma homocysteine.
    Chan NN; Chow FC
    Lancet; 2001 Nov; 358(9295):1811; author reply 1811-2. PubMed ID: 11734263
    [No Abstract]   [Full Text] [Related]  

  • 20. Safe use of gemfibrozil in uremic patients on continuous ambulatory peritoneal dialysis.
    Lucatello A; Sturani A; Di Nardo AM; Cocchi R; Fusaroli M
    Nephron; 1998; 78(3):338. PubMed ID: 9546699
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.